BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile


Erimos Pharmaceuticals 

930 Main Campus Drive
Suite 100
Raleigh  North Carolina  27606  U.S.A.
Phone: 919-821-5204 Fax: 919-821-5309


View Clinical Trials from BioPharm Insight

Erimos is a growing biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics to treat cancer. Our targeted technology is aimed at eradicating tumors by preventing tumor cell replication and promoting selective tumor cell death (apoptosis).

Erimos has exclusive license for nordihydroguaiaretic acid (NDGA) derivatives from The Johns Hopkins University. We have developed a novel process to extract the NDGA from the resin of the leaves of Larrea tridentate, a desert plant indigenous to the southwestern US and Mexico. Terameprocol (EM-1421), our lead candidate, is a semi-synthetic derivative of NDGA and is designed to target specific differences between normal human cells and those cells that are abnormally aggressively dividing. Our goal is to develop effective medicines with a low toxicity profile for serious diseases with high unmet medical need.

Erimos has several clinical studies ongoing: a Phase I/II study to determine the maximum tolerated dose of terameprocol in adults with recurrent high grade glioma; a Phase I study of intravenous terameprocol in adults with hematological malignancies and a Phase I 24 hour infusion study of terameprocol for refractory and metastatic solid tumors.

Erimos is actively growing and pursuing a near-term business strategy which includes collaborations with interested parties in drug discovery, development and commercialization. Our ongoing research supports a broad-spectrum market opportunity backed by patented global intellectual property.

Erimos has corporate offices, research and development, and laboratory facilities in Raleigh, NC. Additional corporate offices are located in Houston, TX. Erimos also has a processing plant in Juarez, Mexico.

Last Updated: 02-20-2008

 Key Statistics

Ownership: Private

Web Site: Erimos Pharmaceuticals

 Company News
Erimos Pharmaceuticals Announces Phase I Continuos Intravenous Infusion Study of Terameprocol (EM-1421) 6/11/2007 2:03:39 PM
Erimos Pharmaceuticals Names Dr. Scott Mohrland as President and Chief Executive Officer 4/17/2007 10:41:23 AM
BioSpace Partners with CED and NC Biotech Center to Showcase North Carolina’s Life Science Community 3/28/2007 2:30:17 PM
Erimos Pharmaceuticals Announces Phase I/Phase II Study of Terameprocol (EM-1421) In Conjunction with New Approaches to Brain Tumor Therapy (NABTT) Consortium 3/26/2007 12:35:10 PM
Erimos Pharmaceuticals Names Members To Scientific Advisory Board 8/9/2006 11:22:13 AM
North Carolina State University, Erimos Pharmaceuticals Seek Patent For Potential Flu Treatment 4/4/2006 1:24:52 PM
Triangle Science Collaboration Could Impact Influenza, Avian Flu Treatment 4/4/2006 12:59:27 PM
Erimos Pharmaceuticals Announces Phase I Study Of EM-1421 Initiated At Three U.S. Sites 1/24/2006 11:16:03 AM
BioSpace Releases Its 3rd Edition Of Bio NC™ 10/19/2005 5:12:33 PM
New Companies To Be Showcased At Biotech Event10/19/2005 5:11:29 PM